US4765985A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Devices and methods for treating memory impairment
Assignee: Novartis Corp
•
Filing: 1987-05-20
•
Granted: 1988-08-23
•
Expires: 2007-05-20
Abstract
Abstract A device for the transdermal administration of a drug for the treatment of memory impairment comprising: (a) a drug impermeable backing layer; (b) a drug permeable rate controlling membrane sealed to one side of said backing layer as to define at least one drug reservoir compartment therebetween; (c) an adhesive layer; (d) a drug or composition thereof within said hollow drug reservoir; said drug comprising a memory improving effective amount of a compound having the formula ##STR1## wherein X 1 , X 2 , X 3 , X 4 , independently represent --H or lower alkyl; said composition comprising said drug and at least one pharmaceutically acceptable adjunct; whereby said drug is delivered in a controlled, continuous manner to a patient to which said device has been applied.
Inventors
- 👤 Lewis J. Leeson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 18:35
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/435; A61K31/44; A61K31/445; A61K31/455; A61K31/47; A61K31/485; A61K9/0002; A61K9/0004
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
128 words
A device for the transdermal administration of a drug for the treatment of memory impairment comprising (a) a drug impermeable backing layer; (b) a drug permeable rate controlling membrane sealed to one side of said backing layer as to define at least one drug reservoir compartment therebetween; (c) an adhesive layer; (d) a drug or composition thereof within said hollow drug reservoir; said drug comprising a memory improving effective amount of a compound having the formula ##STR11## wherein X 1 , X 2 , X 3 , X 4 , independently represent H or lower alkyl; said composition comprising said drug and at least one pharmaceutically acceptable adjunct; whereby said drug is delivered in a controlled, continuous manner to a patient to which said device has been applied.
Claim 2
Independent Claim
128 words
A device for the transdermal administration of a drug for the treatment of memory impairment comprising (a) a drug impermeable backing layer; (b) a drug permeable rate controlling membrane sealed to one side of said backing layer as to define at least one drug reservoir compartment therebetween; (c) an adhesive layer; (d) a drug or composition thereof within said hollow drug reservoir; said drug comprising a memory improving effective amount of a compound having the formula ##STR11## wherein X 1 , X 2 , X 3 , X 4 , independently represent H or lower alkyl; said composition comprising said drug and at least one pharmaceutically acceptable adjunct; whereby said drug is delivered in a controlled, continuous manner to a patient to which said device has been applied.
Claim 3
Dependent Claim
43 words
A method of treating memory impairment in a mammal in need thereof comprising administering to said patient the device of claim 1 so that a continuous memory impairment treating effective amount of said drug is delivered to said mammal in a controlled manner.
Claim 4
Dependent Claim
16 words
The method of claim 2 wherein said memory impairmemt is senile dementia of the Alzheimer's type.
Claim 5
Dependent Claim
10 words
The device of claim 1 wherein the compound is physostigmine.
Claim 6
Dependent Claim
14 words
The device of claim 1 wherein the compound is combined with a suitable excipient.
Claim 7
Dependent Claim
29 words
The device of claim 1 further comprising an anticholinergic agent in an amount to reduce cholinergic side effects wherein the anticholinergic agent does not cross the blood brain barrier.
Claim 8
Dependent Claim
11 words
The device of claim 6 wherein the anticholinergic agent is methscopolamine.
Claim 9
Dependent Claim
13 words
The device of claim 6 wherein the anticholinergic agent is homatropine methyl bromide.
Claim 10
Dependent Claim
10 words
The method of claim 2 wherein the compound is physostigmine.
Claim 11
Dependent Claim
14 words
The method of claim 2 wherein the compound is combined with a suitable excipient.
Claim 12
Dependent Claim
30 words
The method of claim 2 further comprising administering an anticholinergent agent in an amount to reduce cholinergic side effects wherein the anticholinergent agent does not cross the blood brain barrier.
References Cited (Backward Citations)
US3797494A
Cited
US3760806A
Cited
US3760805A
Cited
US3742951A
Cited
US3742951B1
Cited
US3996934A
Cited
US3764984A
Cited
US3845770A
Cited
US3921636A
Cited
US3916899A
Cited
US4144317A
Cited
US3987790A
Cited
US4031894A
Cited
US4137300A
Cited
EP0040861A1
Cited
US4278667A
Cited
EP0089548A1
Cited
EP0108218A2
Cited
EP0116238A1
Cited
GB2142822A
Cited
GB2163347A
Cited
DE3528979A1
Cited
EP0178140A2
Cited
US4597961A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-23 | 1992-02-22 | 1992-08-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-23 | 1996-02-22 | 1996-08-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-23 | 2000-02-22 | 2000-08-23 | $7700.00 | Window Closed / Lapsed |